Evaluation of EBV transformation of human memory B-cells isolated by FACS and MACS techniques

References

• Babcock GJ, Decker LL, Volk M, Thorley-Lawson D. 1998. EBV persistence in memory B-cells in vivo. Immunity 9:395–404.
   PubMed Web of Science ®Google Scholar
• Beck JC, Beiswanger CM, John EM, Satariano E, West D. 2001. Successful transformation of cryopreserved lymphocytes a resource for epidemiological studies. Cancer Epidemiol Biomarkers Prevent. 10:551–554.
   PubMed Web of Science ®Google Scholar
• Bourke E, Bosisio D, Golay J, Polentarutti N, Mantovani A. 2003. The toll-like receptor repertoire of human B-lymphocytes: inducible and selective expression of TLR9 and TLR10 in normal and transformed cells. Blood 102:956–963.
   PubMed Web of Science ®Google Scholar
• Chen C, Johnston T, Jeon H, Gedaly R, McHugh P, Ranjan D. 2009. Cyclosporine promotes Epstein–Barr virus-infected human B-cell transformation assayed by three correlated assay methods. Transplant Proc. 1:366–370.
   Web of Science ®Google Scholar
• Dainiak MB, Kumar A, Galaev IY, Mattiasson B, editors. 2007. Methods in cell separation. Cell separation. London: Springer. p. 1–18.
   Google Scholar
• Hur DY, Lee MH, Kim JW, Kim JH, Shin YK, Rho JK, Kwack KB, Lee WJ, Han BG. 2005. CD19 signalling improves the Epstein-Barr virus‐induced immortalization of human B-cells. Cell Prolif. 38:35–45.
   PubMed Web of Science ®Google Scholar
• Iskra S, Kalla M, Delecluse HJ, Hammerschmidt W, Moosmann A. 2010. Toll-like receptor agonists synergistically increase proliferation and activation of B-cells by EBV. J Virol. 84:3612–3623.
   PubMed Web of Science ®Google Scholar
• Manor E. 2008. Human plasma accelerates immortalization of B-lymphocytes by Epstein-Barr virus. Cell Prolif. 41:292–298.
   PubMed Web of Science ®Google Scholar
• Middeldorp JM, Brink AA, van den Brule AJ, Meijer CJ. 2003. Pathogenic roles for Epstein-Barr virus (EBV) gene products in EBV-associated proliferative disorders. Crit Rev Oncol Hematol. 45:1–36.
   PubMed Web of Science ®Google Scholar
• Oh HM, Oh JM, Choi SC, Kim SW, Han WC, Kim TH, Park DS, Jun CD. 2003. An efficient method for the rapid establishment of Epstein‐Barr virus immortalization of human B-lymphocytes. Cell Prolif. 36:191–197.
   PubMed Web of Science ®Google Scholar
• Pelloquin F, Lamelin JP, Lenoir GM. 1986. Human B-lymphocyte immortalization by Epstein-Barr virus in the presence of cyclosporin A. In Vitro Cell Devel Biol. 22:689–689.
   PubMed Web of Science ®Google Scholar
• Price AM, Luftig MA. 2013. Dynamic Epstein–Barr virus gene expression on the path to B-cell transformation. Adv Virus Res. 88:279–313.
   Web of Science ®Google Scholar
• Shokrgozar MA, Shokri F. 2001. Enumeration of hepatitis B surface antigen‐specific B-lymphocytes in responder and non‐responder normal individuals vaccinated with recombinant hepatitis B surface antigen. Immunology 104:75–79.
   PubMed Web of Science ®Google Scholar
• Steinitz M, editor. 2014. Production of human monoclonal antibodies by the Epstein-Barr virus method. Human monoclonal antibodies. London: Springer. p. 111–122.
   Google Scholar
• Taswell C. 1981. Limiting dilution assays for the determination of immunocompetent cell frequencies. I. Data analysis. J Immunol. 126:1614–1619.
   PubMed Web of Science ®Google Scholar
• Tjandra JJ, Ramadi L, McKenzie IF. 1990. Development of human anti-murine antibody (HAMA) response in patients. Immunol Cell Biol. 68:367–376.
   PubMed Web of Science ®Google Scholar
• Traggiai E, editor. 2012. Immortalization of human B-cells: Analysis of B-cell repertoire and production of human monoclonal antibodies. Antibody methods and protocols. London: Springer. p. 161–170
   Google Scholar
• Traggiai E, Becker S, Subbarao K, Kolesnikova L, Uematsu Y, Gismondo MR, Murphy BR, Rappuoli R, Lanzavecchia A. 2004. An efficient method to make human monoclonal antibodies from memory B-cells: potent neutralization of SARS coronavirus. Nat Med. 10:871–875.
   PubMed Web of Science ®Google Scholar
• Weiner LM, Surana R, Wang S. 2010. Monoclonal antibodies: Versatile platforms for cancer immunotherapy. Nat Rev Immunol. 10:317–327.
   PubMed Web of Science ®Google Scholar
• Wrammert J, Smith K, Miller J, Langley T, Kokko K, Larsen C, Zheng NY, Mays I, Garman L, Helms C, et al. 2008. Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature 453:667–671.
   PubMed Web of Science ®Google Scholar
• Younesi V, Nikzamir H, Yousefi M, Khoshnoodi J, Arjmand M, Rabbani H, Shokri F. 2010. Epstein Barr virus inhibits the stimulatory effect of TLR7/8 and TLR9 agonists but not CD40 ligand in human B-lymphocytes Microbiol Immunol. 54:534–541.
   PubMed Web of Science ®Google Scholar
• Younesi V, Shirazi FG, Memarian A, Amanzadeh A, Jeddi-Tehrani M, Shokri F. 2014. Assessment of the effect of TLR7/8, TLR9 agonists and CD40 ligand on the transformation efficiency of Epstein-Barr virus in human B-lymphocytes by limiting dilution assay. Cytotechnology 66:95–105.
   PubMed Web of Science ®Google Scholar
• Young LS, Rickinson AB. 2004. Epstein-Barr virus: 40 years on. Nat Rev Cancer. 4:757–768.
   PubMed Web of Science ®Google Scholar
• Yousefi M, Khosravi-Eghbal R, Mahmoudi AR, Jeddi-Tehrani M, Rabbani H, Shokri F. 2013a. Comparative in vitro and in vivo assessment of toxin neutralization by anti-tetanus toxin monoclonal antibodies. Hum Vac Immunother. 10:16–15.
   Web of Science ®Google Scholar
• Yousefi M, Tahmasebi F, Younesi V, Razavi A, Khoshnoodi J, Bayat AA, Abbasi E, Rabbani H, Jeddi-Tehrani M, Shokri F. 2013b. Characterization of neutralizing monoclonal antibodies directed against tetanus toxin fragment C. J Immunotoxicol. 11:28–34.
   PubMed Web of Science ®Google Scholar